Long for a Longtime or until they make me an offer I cant' Refuse
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
His last three articles bashed AVXL...and I thought they were short...now no position...
I have always thought he would end up in an orange jump suit with many Bubas trying to invade his private parts...
Who knows... options is a scary game...My attitude has always been to sell call options at a price I would be comfortable at giving the stock up at..we are a long way from that. JMO
He pissed off some very powerful and influential people and if you remember Hilberbeast mentioned him specifically.
I always believed Shrkeli was the reason they investigated AVXL along with complaints from retail investors about the massacre. Shrkeli was a major part of the Cabal that profited from the BIG SHORT. IMO
Isn't this what a adaptive trial is all about...can't they change the parameters as they go? A question for anyone that knows..
I say this all the time. lots of peeps expect this all to happen in 3 months...
Short duration and limited patients...the best news is it can allow Anavex to show how effective 273 is against seizures. IMO And I would not be surprised to see the Retts organization throw in a few bucks.
The SEC staff recently advised Company’s legal counsel that the staff did not intend to recommend enforcement action by the Commission against the Company in connection with the investigation previously described in the Company’s 2015 Report on Form 10-K.
http://ih.advfn.com/p.php?pid=nmona&article=72196841
http://www.ddn-news.com/lib/sitefiles/pdf/Issues/DDNEWS_0716.pdf
Check out pages 16 & 17
Cabal working overtime to trash AVXL..I wonder why?????
Early on the good doctor stated his approach was to ensure that they would not go into a phase 3 study without a verifiable indication that the drug would be successful.... Now if you believe this is all a scam then I will not and cannot convince you that the current data is positive.
Here is some light reading for you...study this
http://www.fda.gov/downloads/Drugs/.../Guidances/ucm201790.pdf
If I am not mistaken so far Anavex's approach to solving the AD problem is 0 for 0. Most if not all of the others went after the symptoms.
Doesn't the terms of the LPC funding prevent them from shorting the stock?
Sometimes you win..sometimes you lose..and sometimes you break even..such is life.
My investing instinct raised a red flag...but I did not respond.. My bad...should have... Not complaining got in right.
On every interview he stressed the need for a bigger trials and even indicated he felt it was more important that peeps daily lives improved and played down the data.
Seemed to be another coordinated attack....stock started dropping before PR came out...selling begot selling...the poster wasn't great but it wasn't bad...I still believe the drug is better than SOC and with some well placed PR's about some upcoming catalysts we should rebound. JMO
I may be wrong but didn't the poster prove that we have a drug that is better than the current SOC and may have other benefits. I would have to think some analysts will take notice and BP may also take a long look at what is happening with Anavex. Plus has any other AD drug done as well?
Wolfman, good to see you back...last poster was presented at 9:30 that why you got it then...this one gets presented at 1:00
The good news is we won't have a morning gap to deal with. Good luck to all longs it has been an interesting journey that begins again at 1:00 tomorrow.
I guess we will find out in less than 30 hours...
Falconer,
You da Man!.... thanks for your contributions to this group..
There are other catalysts to consider. Over the next few Months they should happen.
Great post as usual. You should not be surprised that there was no mention of Anavex.
The only useful new treatment will be Anavex 2-73; of which there was no mention.
Funding for this initiative was provided by Axovant Sciences Ltd.
We will.
So you are saying these events were observed in only three people?
16 Events reported with the Preferred Term of ‘Therapeutic Response
Unexpected’. A sample of verbatim terms reported include:
Improved Engagement with Family/Friends
Improvement in Mood
Increased Independent Activity
Feeling Happier
Improved Alertness
Better Coordination
Better Coping
Same Dr. Hampel..
“ANAVEX 2-73 data presented today is prerequisite information in order to progress into Phase 2/3 placebo controlled studies,” said Professor Harald Hampel, MD, PhD, Professor and AXA Research Fund Chair at Sorbonne Universities’ Pierre and Marie Curie University (UPMC), Paris, France and member of Anavex’s Scientific Advisory Board. “ANAVEX 2-73’s specific molecular biology, combined with its observed favorable safety and tolerability profile makes it a very interesting candidate to explore in further clinical trials of different neurological diseases.”
From other posts I have read...the missing piece on todays PR is the PK data which is needed to design Phase 3. I am not a doctor and am just relaying info.
Here is a link http://www.appliedclinicaltrialsonline.com/pk-late-phase-trials
16 Events reported with the Preferred Term of ‘Therapeutic Response
Unexpected’. A sample of verbatim terms reported include:
* Improved Engagement with Family/Friends
* Improvement in Mood
* Increased Independent Activity
* Feeling Happier
* Improved Alertness
* Better Coordination
* Better Coping
This didn't stop them last year when the twitter babe took pictures and made comments (not nice) about Anavex's posters...which fed papa troll. I expect the same this time....If you are an attendee you have a phone app that I believe will have at least the abstracts maybe the posters.
Kinda makes you go HMMMMMM!
Amen to that!
I think this time we have more statistically significant data and possibly some other surprises.